Skip to main navigation Skip to search Skip to main content

A Phase 2a, Randomized, Open-Label, Active Control, Multi-Center Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de novo Kidney Transplant Recipients

Project: Research

Project Details

StatusFinished
Effective start/end date12/14/17 → 06/30/24

Funding

  • Astellas Pharma Global Development Incorporated: $132,910.20